Drug packages containing Wegovy, Ozempic and Mounjaro syringes are seen in a store in Mitte, Germany, on July 11, 2024.
Image Alliance | Image Alliance | Getty Images
all doses Novo NordiskPopular weight loss injections wiggs Diabetes drug Ozempic is now available in the U.S., according to one company renew Wednesday’s U.S. Food and Drug Administration drug shortage database.
This marks Novo Nordisk’s efforts increase supply As U.S. demand continues to soar, some of those weekly doses are starting to pay off
A previous update said Wegovy’s lowest dose (25 mg) remains in short supply.
Multiple doses of Wegovy and Ozempic’s active ingredient, semaglutide, have been on the FDA’s shortage list since early 2022.
Wednesday’s update raises the possibility that the FDA may remove the blockbuster shots from its shortage list entirely, which could prevent compounding pharmacies from producing customized and often cheaper versions of these brand-name drugs.
Novo Nordisk said in a statement that all doses of Wegovy and Ozempic are regularly shipped to wholesalers. The Danish drugmaker said the FDA update was the result of significant investments it has made in expanding manufacturing capabilities and “ongoing communication” with the agency.
Still, Novo Nordisk said that even if a drug is listed as available, patients may not always be able to get their prescription filled immediately at a specific pharmacy.
“Our intentional approach to gradually increasing supply in the U.S. market is working,” Novo Nordisk said. “We will continue to prioritize continuity of patient care, closely monitor market dynamics and chart prescribing trends.”
A week ago, Novo Nordisk asked the FDA Prevent compounding pharmacies Produce unapproved versions of Wegovy and Ozempic, arguing that these drugs are too complex for these manufacturers to produce safely.
Earlier this month, the FDA removed the active ingredient in tirzepatide Eli Lilly and Companyof Diet Pill Zepbound and diabetes treatment Mounjaro also appear on its shortage list. But a trade group representing some of the compound’s manufacturers sued the FDA, and the agency said it would reconsider its decision to remove tilsiparatide from the shortage list.
